Correction to: SEOM clinical guideline for treatment of kidney cancer (2017)

Excerpt

The conflict of interest declaration was published incorrectly in the original version. The correct conflict of interest declaration should read as follows: E. Gallardo has served as a consultant or Advisory Role to Pfizer, Bayer, Roche, Ipsen, Novartis, EUSA Pharma, BMS; serve as speaker to Bayer, Ipsen, Pfizer, Roche, BMS, Novartis; has received a Grant support from Bayer, Ipsen; has received Travel grants from Bayer, Ipsen, Roche, Novartis, Pfizer, GSK. M. J. Méndez-Vidal has received honoraria and/or travel support from Janseen-Cilag, Bayer, Sanofi Aventis, Astellas Medivation, Roche, Bristol-Myers Squibb, Novartis, Pfizer, EISAI and Ipsen. J. L. Pérez-Gracia has served as a consultant to Bristol-Myers Squibb and Roche; has received research and travel grants and lecture fees from Bristol-Myers Squibb and Roche. Has received research and travel grants from MSD. J. M. Sepúlveda-Sanchez has no conflict of interest to declare M. Campayo has received honorariums and travels grants from Pfizer, Novartis, Bristol-Myers Squibb and Bayer; has served as advisory role to Pfizer, and Bayer. I. Chirivella-González has received research fundings or consulting honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol, Janssen, Novartis, Pfizer, Roche and Sanofi. X. García-del-Muro has served as consultant or advisory board to Pzifer, Bristol-Myers Squibb, Ipsen, Roche, Lilly, PharmaMar, EusaPharma; has served as speaker to Pfizer, Bristol-Myers Squibb, Ipsen and PharmaMar; has received research grants from AstraZeneca; has received travel and/or accommodation grants from Pfizer and Bristol-Myers Squibb. A. González-del-Alba has served as advisory role or consultant and has received travel grants and/or speaker honoraria from Pierre Fabre, Roche, Bristol-Myers Squibb, MSD, Pizer, Novartis, Bayer, Janssen, Sanofi, Astellas, Ipsen, EUSA pharma and EISAI and has received research funding from Astellas. E. Grande has received honoraria for advisory boards, meetings, and/or lectures from Pfizer, Bristol-Myers Squibb, IPSEN, Roche, Eisai, Eusa Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, and Celgene, and has received unrestricted research grants from Pfizer, AstraZeneca, MTEM/Threshold, Roche, IPSEN, and Lexicon. Cristina Suárez has served as advisory board to BMS, IPSEN, Novartis, Pfizer; has received travel grant to BMS; has served as speaker to Astrazeneca and Pfizer. …